Immigration and viral hepatitis

Journal of Hepatology

Volumn 63, Issue 2, 2015, Pages 515-522

  Sharma, Suraj ^a   Carballo, Manuel ^b   Feld, Jordan J ^a   Janssen, Harry L A ^a,c  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Cirrhosis; Immigration; Viral hepatitis

Indexed keywords

ARTICLE; CANADA; CHRONIC LIVER DISEASE; EUROPEAN UNION; HEPATITIS B; HEPATITIS C; HUMAN; IMMIGRANT; IMMIGRATION; LIVER CIRRHOSIS; MASS SCREENING; MORTALITY; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; REFUGEE; UNITED STATES; VACCINATION; VIRUS HEPATITIS; HEALTH; HEPATITIS, VIRAL, HUMAN; MIGRATION; MORBIDITY;

EMIGRATION AND IMMIGRATION; GLOBAL HEALTH; HEPATITIS, VIRAL, HUMAN; HUMANS; MORBIDITY; PREVALENCE;

EID: 84942831134     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2015.04.026     Document Type: Review

References (87)

1. WHO. Hepatitis B Fact Sheet. 〈http://www.who.int/mediacentre/factsheets/fs204/en〉.
2. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004;11:97-107.
3. Perz JF, Armstrong GL, Farrington LA, Hutin YJF, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006;45:529-538.
4. Centers for Disease Control and Prevention (CDC). World Hepatitis Day Factsheet. 〈http://www.cdc.gov/Features/WorldHepatitisDay〉.
5. Mahoney FJ. Update on diagnosis, management, and prevention of hepatitis B virus infection. Clin Microbiol Rev 1999;12:351-366.
6. Kane A, Lloyd J, Zaffran M, Simonsen L, Kane M. Transmission of hepatitis B, hepatitis C and human immunodeficiency viruses through unsafe injections in the developing world: model-based regional estimates. Bull World Health Organ 1999;77:801-807.
7. Kim WR. Epidemiology of hepatitis B in the United States. Hepatology 2009:S28-S34.
8. Simard EP, Miller JT, George PA, Wasley A, Alter MJ, Bell BP, et al. Hepatitis B vaccination coverage levels among healthcare workers in the United States, 2002-2003. Infect Control Hosp Epidemiol 2007;28:783-790.
9. Centers for Disease Control and Prevention (CDC). Implementation of newborn hepatitis B vaccination-worldwide. MMWR 2008;57:1249-1252.
10. WHO. World Health Organization. Hepatitis B vaccines: WHO position paper. Wkly Epidemiol Rec 2004;79:255-263.
11. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013;57:1333-1342.
12. Global Burden of Disease Working Group. Global burden of disease (GBD) for hepatitis C. J Clin Pharm 2004;44:20-29.
13. Guerra J, Garenne M, Mohamed MK, Fontanet A. HCV burden of infection in Egypt: results from a nationwide survey. J Viral Hepat 2012;19:560-567.
14. Frank C, Mohamed MK, Strickland GT, Lavanchy D, Arthur RR, Magder LS, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000;355:887-891.
15. Sievert W, Altraif I, Razavi HA, Abdo A, Ahmed EA, Alomair A, et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int 2011;31:61-80.
16. Miller FD, Abu-Raddad LJ. Evidence of intense ongoing endemic transmission of hepatitis C virus in Egypt. Proc Natl Acad Sci U S A 2010;107:14757-14762.
17. HCV iatrogenic and intrafamilial transmission in Greater Cairo, Egypt. Gut 2010;59:1554-1560.
18. Lu J, Zhou Y, Lin X, Jiang Y, Tian R, Zhang Y, et al. General epidemiological parameters of viral hepatitis A, B, C, and E in six regions of China: a crosssectional study in 2007. PLoS One 2009;4:e8467.
19. Waheed Y, Shafi T, Safi SZ, Qadri I. Hepatitis C virus in Pakistan: a systematic review of prevalence, genotypes and risk factors. World J Gastroenterol 2009;15:5647-5653.
20. Liu F, Chen K, He Z, Ning T, Pan Y, Cai H, et al. Hepatitis C seroprevalence and associated risk factors, Anyang, China. Emerging Infect Dis 2009;15: 1819-1822.
21. Xia X, Luo J, Bai J, Yu R. Epidemiology of hepatitis C virus infection among injection drug users in China: systematic review and meta-analysis. Public Health 2008;122:990-1003.
22. Esteban JI, Sauleda S, Quer J. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol 2008;48:148-162.
23. Naoumov NV. Hepatitis C virus infection in Eastern Europe. J Hepatol 1999;31:84-87.
24. Mühlberger N, Schwarzer R, Lettmeier B, Sroczynski G, Zeuzem S, Siebert U. HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health 2009;9:34.
25. Lvov DK, Samokhvalov EI, Tsuda F, Selivanov NA, Okamoto H, Stakhanova VM, et al. Prevalence of hepatitis C virus and distribution of its genotypes in Northern Eurasia. Arch Virol 1996;141:1613-1622.
26. Chak E, Talal AH, Sherman KE, Schiff ER, Saab S. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int 2011;31:1090-1101.
27. Williams IT, Bell BP, Kuhnert W, Alter MJ. Incidence and transmission patterns of acute hepatitis C in the United States, 1982-2006. Arch Intern Med 2011;171:242-248.
28. Fischer GE, Schaefer MK, Labus BJ, Sands L, Rowley P, Azzam IA, et al. Hepatitis C virus infections from unsafe injection practices at an endoscopy clinic in Las Vegas, Nevada, 2007-2008. Clin Infect Dis 2010;51:267-273.
29. UN. UN International Migration Wallchart 2013. 〈http://www.un.org/en/development/desa/population/publications/migration/migration-wallchart-2013.shtml〉.
30. OECD. World Migration in Figures. 〈http://www.oecd.org/els/mig/World-Migration-in-Figures.pdf〉.
31. Security UDOH. Immigration statistics 2013. 〈http://www.dhs.gov/immigration-statistics〉.
32. Eurostat. Immigration in the EU. 〈http://ec.europa.eu/dgs/home-affairs/e-library/docs/infographics/immigration/migration-in-eu-infographic-en.pdf〉.
33. Wasley A, Kruszon-Moran D, Kuhnert W, Simard EP, Finelli L, McQuillan G, et al. The prevalence of hepatitis B virus infection in the United States in the era of vaccination. J Infect Dis 2010;202:192-201.
34. Pollack HJ, Kwon SC, Wang SH, Wyatt LC, Trinh-Shevrin CAAHBP Coalition. Chronic hepatitis B and liver cancer risks among Asian immigrants in New York City: results from a large, community-based screening, evaluation, and treatment program. Cancer Epidemiol Biomarkers Prev 2014;23: 2229-2239.
35. Shire AM, Sandhu DS, Kaiya JK, Oseini AM, Yang JD, Chaiteerakij R, et al. Viral hepatitis among Somali immigrants in Minnesota: association of hepatitis C with hepatocellular carcinoma. Mayo Clin Proc 2012;87:17-24.
36. Kowdley KV, Wang CC, Welch S, Roberts H, Brosgart CL. Prevalence of chronic hepatitis B among foreign-born persons living in the United States by country of origin. Hepatology 2012;56:422-433.
37. ECDC. Surveillance and epidemiology of hepatitis B and C in Europe - A review. 〈http://www.eurosurveillance.org/images/dynamic/EE/V13N21/art18880.pdf〉.
38. ECDC. Assessing the burden of key infectious diseases affecting migrant populations in the EU/EEA. 〈http://ecdc.europa.eu/en/publications/Publications/assessing-burden-disease-migrant-populations.pdf〉.
39. Marschall T, Kretzschmar M, Mangen MJ, Schalm S. High impact of migration on the prevalence of chronic hepatitis B in the Netherlands. Eur J Gastroenterol Hepatol 2008;20:1214-1225.
40. Rossi C, Shrier I, Marshall L, Cnossen S, Schwartzman K, Klein MB, et al. Seroprevalence of chronic hepatitis B virus infection and prior immunity in immigrants and refugees: a systematic review and meta-analysis. PLoS One 2012;7:e44611.
41. Pottie K, Greenaway C, Feightner J, Welch V, Swinkels H, Rashid M, et al. Evidence-based clinical guidelines for immigrants and refugees. CMAJ 2011;183:E824-E925.
42. WHO. Hepatitis C. 〈http://www.euro.who.int/en/health-topics/communicable-diseases/hepatitis/data-and-statistics/hepatitis-c〉.
43. Vriend HJ, Van Veen MG, Prins M, Urbanus AT, Boot HJ, Op De Coul ELM. Hepatitis C virus prevalence in The Netherlands: migrants account for most infections. Epidemiol Infect 2013;141:1310-1317.
44. Uddin G, Shoeb D, Solaiman S, Marley R, Gore C, Ramsay M, et al. Prevalence of chronic viral hepatitis in people of south Asian ethnicity living in England: the prevalence cannot necessarily be predicted from the prevalence in the country of origin. J Viral Hepat 2010;17:327-335.
45. Centers for Disease Control and Prevention (CDC). CDC technical instructions for civil surgeons. 〈http://www.cdc.gov/immigrantrefugeehealth/exams/ti/civil/technical-instructions-civil-surgeons.html〉.
46. Centers for Disease Control and Prevention (CDC). CDC technical instructions for vaccination for civil surgeons. 〈http://www.cdc.gov/immigrantrefugeehealth/exams/ti/civil/vaccination-civil-technical-instructions.html〉.
47. Centers for Disease Control and Prevention (CDC). Screening for hepatitis during the domestic medical examination. 〈http://www.cdc.gov/immigrantrefugeehealth/guidelines/domestic/hepatitis-screening-guidelines.html〉.
48. Canada I. Immigration medical examination instructions. 〈http://www.cic.gc.ca/english/department/partner/pp/〉.
49. Van Damme P, Leuridan E, Hendrickx G, Vorsters A, Theeten H, Leino T, et al. Should Europe have a universal hepatitis B vaccination programme? BMJ 2013;347:f4057.
50. Kretzschmar M, Mangen M-J, van de Laar M, de Wit A. Model based analysis of hepatitis B vaccination strategies in the Netherlands. Vaccine 2009;27:1254-1260.
51. Tugwell P, Pottie K, Welch V, Ueffing E, Chambers A, Feightner J, et al. Evaluation of evidence-based literature and formulation of recommendations for the clinical preventive guidelines for immigrants and refugees in Canada. CMAJ 2011;183:E933-E938.
52. Taylor VM, Jackson JC, Pineda M, Pham P, Fischer M, Yasui Y. Hepatitis B knowledge among Vietnamese immigrants: implications for prevention of hepatocellular carcinoma. J Cancer Educ 2000;15:51-55.
53. Strong C, Hur K, Kim F, Pan J, Tran S, Juon H-S. Sociodemographic characteristics, knowledge and prevalence of viral hepatitis infection among vietnamese Americans at community screenings. J Immigr Minor Health 2015;17:298-301.
54. DesMeules M, Gold J, McDermott S, Cao Z, Payne J, Lafrance B, et al. Disparities in mortality patterns among Canadian immigrants and refugees, 1980-1998: results of a national cohort study. J Immigr Health 2005;7:221-232.
55. Ontario Public Health. Ontario burden of infectious diseases study. 〈http://www.publichealthontario.ca/en/eRepository/ONBoID-ICES-Report-ma18.pdf〉.
56. Canadian Liver Foundation. Liver disease in Canada - A crisis in the making. 〈http://www.liver.ca/support-liver-foundation/advocate/Liver-Disease-in-Canada-Report.aspx〉.
57. Chen W, Tomlinson G, Krahn M, Heathcote J. Immigrant patients with chronic hepatitis C and advanced fibrosis have a higher risk of hepatocellular carcinoma. J Viral Hepat 2012;19:574-580.
58. Chang ET, Keegan THM, Gomez SL, Le GM, Clarke CA, So SKS, et al. The burden of liver cancer in Asians and Pacific Islanders in the Greater San Francisco Bay Area, 1990 through 2004. Cancer 2007;109:2100-2108.
59. Hutton DW, Tan D, So SK, Brandeau ML. Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B. Ann Intern Med 2007;147:460-469.
60. Wan DW, Tzimas D, Smith JA, Kim S, Araujo J, David R, et al. Risk factors for early-onset and late-onset hepatocellular carcinoma in Asian immigrants with hepatitis B in the United States. Am J Gastroenterol 2011;106:1994-2000.
61. McGowan CE, Fried MW. Barriers to hepatitis C treatment. Liver Int 2012;32:151-156.
62. Malespin M, Wong S, Siqueira F, Luc B, Ravaee B, Vainder C, et al. Barriers to treatment of hepatitis B in an urban Chinatown community. J Clin Gastroenterol 2012;46:e66-70.
63. McGowan CE, Monis A, Bacon BR, Mallolas J, Gonçales FL, Goulis I, et al. A global view of hepatitis C: physician knowledge, opinions, and perceived barriers to care. Hepatology 2013;57:1325-1332.
64. Thomas DL. Curing hepatitis C with pills: a step toward global control. Lancet 2010;376:1441-1442.
65. Canadian AIDS Treatment Information Exchange (CATIE). The development and implementation of a multilingual hepatitis C media and educational outreach campaign targetting immigrant populations in Ontario. 〈https://cdc.confex.com/cdc/nphic13/webprogram/Paper33539.html〉.
66. Perumalswami PV, Factor SH, Kapelusznik L, Friedman SL, Pan CQ, Chang C, et al. Hepatitis Outreach Network: a practical strategy for hepatitis screening with linkage to care in foreign-born communities. J Hepatol 2013;58: 890-897.
67. Perumalswami PV, DeWolfe Miller F, Orabee H, Regab A, Adams M, Kapelusznik L, et al. Hepatitis C screening beyond CDC guidelines in an Egyptian immigrant community. Liver Int 2014;34:253-258.
68. Richter C, Beest Ter G, Gisolf EH, van Bentum P, Waegemaekers C, Swanink C, et al. Screening for chronic hepatitis B and C in migrants from Afghanistan, Iran, Iraq, the former Soviet Republics, and Vietnam in the Arnhem region, The Netherlands. Epidemiol Infect 2014;142:2140-2146.
69. Veldhuijzen IK, Wolter R, Rijckborst V, Mostert M, Voeten HA, Cheung Y, et al. Identification and treatment of chronic hepatitis B in Chinese migrants: results of a project offering on-site testing in Rotterdam, The Netherlands. J Hepatol 2012;57:1171-1176.
70. Hepscreen. A repository of good practice screening projects. 〈http://hepscreen.eu/what-can-we-do-about-it/screening/existing-publishedscreening-projects/〉.
71. Pollack H, Wang S, Wyatt L, Peng C-H, Wan K, Trinh-Shevrin C, et al. A comprehensive screening and treatment model for reducing disparities in hepatitis B. Health Aff (Millwood) 2011;30:1974-1983.
72. Arora S, Kalishman S, Thornton K, Dion D, Murata G, Deming P, et al. Expanding access to hepatitis C virus treatment-Extension for Community Healthcare Outcomes (ECHO) project: disruptive innovation in specialty care. Hepatology 2010;52:1124-1133.
73. Grebely J, Oser M, Taylor LE, Dore GJ. Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: action required at the system, provider, and patient levels. J Infect Dis 2013;207:S19-25.
74. Robotin MC, George J. Community-based hepatitis B screening: what works? Hepatol Int 2014;8:478-492.
75. O'Leary MC, Sarwar M, Hutchinson SJ, Weir A, Schofield J, McLeod A, et al. The prevalence of hepatitis C virus among people of South Asian origin in Glasgow - Results from a community based survey and laboratory surveillance. Travel Med Infect Dis 2013;11:301-309.
76. Antonucci G, Mazzotta F, Puoti M, Angeletti C, Girardi E, Santantonio T, et al. Factors associated with access to antiviral treatment in a multicentre crosssectional study of patients with chronic hepatitis B in Italy. J Viral Hepat 2012;19:881-889.
77. Papatheodoridis GV, Tsochatzis E, Hardtke S, Wedemeyer H. Barriers to care and treatment for patients with chronic viral hepatitis in Europe: a systematic review. Liver Int 2014;34:1452-1463.
78. Vedio AB, Ellam H, Rayner F, Stone B, Kudesia G, McKendrick MW, et al. Hepatitis B: report of prevalence and access to healthcare among Chinese residents in Sheffield UK. J Infect Public Health 2013;6:448-455.
79. Giordano C, Druyts EF, Garber G, Cooper C. Evaluation of immigration status, race and language barriers on chronic hepatitis C virus infection management and treatment outcomes. Eur J Gastroenterol Hepatol 2009;21:963-968.
80. Veldhuijzen IK, Toy M, Hahné SJM, De Wit GA, Schalm SW, de Man RA, et al. Screening and early treatment of migrants for chronic hepatitis B virus infection is cost-effective. Gastroenterology 2010;138:522-530.
81. Hahné SJM, Veldhuijzen IK, Wiessing L, Lim T-A, Salminen M, de Laar MV. Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening. BMC Infect Dis 2013;13:181.
82. Helsper CW, Borkent-Raven BA, de Wit NJ, van Essen GA, Bonten MJM, Hoepelman AIM, et al. Cost-effectiveness of targeted screening for hepatitis C in The Netherlands. Epidemiol Infect 2012;140:58-69.
83. Wong WWL, Tu H-A, Feld JJ, Wong T, Krahn M. Cost-effectiveness of screening for hepatitis C in Canada. CMAJ 2015;187:E110-E121.
84. Sroczynski G, Esteban E, Conrads-Frank A, Schwarzer R, Mühlberger N, Wright D, et al. Long-term effectiveness and cost-effectiveness of screening for hepatitis C virus infection. Eur J Public Health 2009;19:245-253.
85. Swinkels H, Pottie K, Tugwell P, Rashid M, Narasiah LCanadian Collaboration for Immigrant and Refugee Health (CCIRH). Development of guidelines for recently arrived immigrants and refugees to Canada: Delphi consensus on selecting preventable and treatable conditions. CMAJ 2011;183:E928-E932.
86. Singer ME, Younossi ZM. Cost effectiveness of screening for hepatitis C virus in asymptomatic, average-risk adults. Am J Med 2001;111:614-621.
87. Razavi, H. The center for disease analysis. Retrieved, 2015, from 〈http://centerforda.com/hep-maps.htm〉.